#NASDAQ #Hong Kong #IPO #Hong Kong Pharma #Kowloon

Hong Kong Pharma's Successful IPO: A New Era for OTC Pharmaceuticals

On January 15, 2025, Hong Kong Pharma Digital Technology Holdings Limited, a prominent player in the over-the-counter (OTC) pharmaceutical cross-border e-commerce supply chain, successfully debuted on the Nasdaq Capital Market under the ticker symbol "HKPD". This marks a significant milestone for the company and the broader pharmaceutical e-commerce landscape in Hong Kong.

Closing of the Initial Public Offering

The company's initial public offering (IPO) culminated in the sale of 1,403,685 ordinary shares at a public offering price of $4.00 per share. Of these, 1,000,000 shares were placed by the company, while 403,685 were sold by existing shareholders. The total gross proceeds from the offering amounted to an impressive $5,614,740, which the company plans to utilize for various strategic initiatives to boost its growth trajectory.

Utilization of Funds

Hong Kong Pharma has earmarked these proceeds for critical advancements in its operations. Specifically, the funds will be allocated for:

• - Development and Upgrade of Systems: Investing in enhanced supply chain enterprise resource planning systems that will streamline operations and increase efficiency.
• - Warehouse Equipment: Procuring state-of-the-art equipment to optimize storage and handling processes, thereby improving overall service delivery.
• - Sales and Marketing Expansion: Growing the sales and marketing team to accelerate market penetration and customer engagement strategies.
• - General Working Capital: Ensuring adequate resources for everyday operational needs and other corporate responsibilities.

With these investments, Hong Kong Pharma aims to strengthen its market position and better serve its clients in the burgeoning field of pharmaceutical e-commerce.

Leadership and Underwriting Partners

The IPO was conducted on a firm commitment basis, led by Bancroft Capital, LLC as the primary underwriter, with Eddid Securities USA Inc. acting as the co-underwriter. The proficient legal advisory came from Bevilacqua PLLC for the company and Ortoli Rosenstadt LLP for the lead underwriter, ensuring all SEC requirements were efficiently met throughout the process.

The Growth of OTC Pharmaceutical E-Commerce

Hong Kong Pharma operates through two key subsidiaries: Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited. Joint Cross Border specializes in providing a complete range of OTC pharmaceutical supply chain services to customers in Mainland China, making foreign OTC products readily available.

The demand for OTC pharmaceuticals continues to surge, driven by consumer trends towards online shopping and cross-border purchases. By offering a comprehensive solution that includes pre-consultation, product review, import/export management, and logistics services, Hong Kong Pharma is well-positioned to capitalize on this expanding market opportunity.

Conclusion

In summary, the successful closing of the IPO is just the beginning for Hong Kong Pharma Digital Technology Holdings Limited, which is set to leverage its new resources toward ambitious growth plans. As the company embarks on this exciting journey, stakeholders and investors alike will be watching closely for how it navigates the dynamic landscape of pharmaceutical e-commerce over the coming months and years.

For further information, you can visit the company's official website at www.9zt.hk.